Reinfection with hepatitis C virus following sustained virological response in injection drug users

Background and Aim:  Despite that 60–90% of injection drug users (IDUs) are infected with hepatitis C virus (HCV) infection, IDUs are often denied therapy based on concerns of reinfection following treatment. However, there are little data in this regard. We evaluated HCV re‐infection following sustained virologic response (SVR) among HCV‐infected IDUs having received HCV treatment in a multidisciplinary program.

[1]  C. Treloar,et al.  Hepatitis C treatment in pharmacotherapy services: increasing treatment uptake needs a critical view. , 2009, Drug and alcohol review.

[2]  J. Raffa,et al.  Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents , 2009, Journal of viral hepatitis.

[3]  B. Conway,et al.  Current Approaches to HCV Infection in Current and Former Injection Drug Users , 2008, Journal of addictive diseases.

[4]  B. Conway,et al.  Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. , 2008, Drug and alcohol dependence.

[5]  D. Vlahov,et al.  Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.

[6]  B. Conway,et al.  Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. , 2007, The International journal on drug policy.

[7]  Fiona Duncan,et al.  Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users , 2007, Journal of gastroenterology and hepatology.

[8]  D. Vlahov,et al.  A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. , 2005, AIDS.

[9]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[10]  O. Dalgard.  Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  den Hollander Jg,et al.  Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. , 2005 .

[12]  B. Rijnders,et al.  Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy. , 2005, AIDS.

[13]  B. Edlin,et al.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Asselah,et al.  Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy , 2003, Gut.

[15]  B. Edlin.  Prevention and treatment of hepatitis C in injection drug users , 2002, Hepatology.

[16]  K. Bjøro,et al.  Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up , 2002, European Addiction Research.